Restaging in gynaecological cancers

Regardless of recent technical developments in the scientific arena, stage is still the most important prognostic factor in gynaecological cancers. Surgical staging is performed in all types of gynaecologic cancers except for cervical cancer. Adjuvant therapies that contribute to survival are planned in the light of information obtained from staging procedures. Therefore, necessary information for further therapeutic management should be revealed by the end of surgical staging. A staging surgery that is not completed for any reason will not only deprive the patient of necessary treatments, but can also cause administration of unnecessary adjuvant treatments. This is especially important, given the undesired effects and cost of both chemotherapy and radiotherapy. A particularly relevant case in point is tumours that look like early stage; this is because upstaging up to 30% has been reported in ovarian and endometrial cancers. As for vulvar cancer, clinical staging has been reported to lead to about 15% over-diagnosis in comparison to surgical staging. Thus, the first step in all gynaecological cancers, except cervical cancer, should be to perform surgical staging when possible and unveil all surgical-pathological prognostic factors in the light of data obtained. Accordingly, restaging surgery should be considered in all cases that had incomplete staging. However, care should be taken to evaluate the benefits to be reaped together with the operative morbidity risk associated with the restaging procedure. This will both ensure accurate planning of postoperative treatment and provide a universal standard of approaching cancer patients and their treatments.

Staging; Restaging; Ovarian cancer; Borderline ovarian cancer; Endometrial cancer; Vulvar cancer; Tubal cancer

[1] American Joint Committee on Cancer Manual for Staging of Cancer. 5" ed., Philadelphia: Lippincott Raven Publishers, 1998.

[2] Odicino F., Favalli G., Zigliani L., Pecorelli S.: "Staging of gynecologic malignancies". Surg. Clin. North. Am., 2001, 81, 753.

[3] Munoz K.A., Harlan L.C., Trimble E.L.: "Patterns of care for women with ovarian cancer in the United States". J. Clin. Oneal., 1997, 15, 3408.

[4] McGowan L.: "Patterns of care in carcinoma of the ovary". Cancer, 1993, 71, 628.

[5] Benedetti-Panici P., Maneschi F., Cutillo G.: "Pelvic and aortic lymphadenectomy". Surg. Clin. North. Am., 2001, 81, 841.

[6] Coukos G., Rubin S.C.: "Early ovarian cancer". Curr. Treat. Options Oneal., 2000, 1, 129.

[7] Ayhan A., Taskiran C., Celik C., Guney I., Yuce K., Ozyar E. et al.: "Is there a survival benefit to adjuvant radiotherapy in high-risk surgical Stage I endometrial cancer?". Gynecol. Oneal., 2002, 86, 259.

[8] Hacker N.: "Vulvar cancer". In: J.S. Berck and N. Hacker (eds.). Practical Gynecological Oncology. Philadelphia，Williams & Wilkins, 2000, 553.

[9] Stier E.A., Barakat R.R., Curtin J.P., Brown C.L., Jones W.B., Hoskins W.J.: "Laparotomy to complete staging of presumed early ovanan cancer". Obstet. Gynecol., 1996, 87, 737.

[10] Soper J.T., Johnson P., Johnson V., Berchuck A., Clarke-Pearson D.L.: "Comprehensive restaging laparotomy in women with apparent early ovarian carcinoma". Obstet. Gynecol., 1992, 80, 949.

[11] Greenlee R.T., Murray T., Bolden S., Wingo P.A.: "Cancer statistics, 2000". Cancer J. Clin., 2000, 50, 7.

[12] Hogberg T., Glimelius B., Nygren P.: "A systematic overview of chemotherapy effects in ovarian cancer". Acta Oneal., 2001, 40, 340.

[13] Young R.C., Decker D.G., Wharton J.T., Piver M.S., Sindelar W.F., Edwards B.K., Smith J.P.: "Staging laparotomy in early ovarian cancer" JAMA, 1983, 250, 3072.

[14] Ayhan A., Bildirici I., Gunalp S., Yuce K.: "Pure dysgerminoma of the ovary: a review of 45 well staged cases". Eur. J. Gynaecol. Oneal., 2000, 21, 98.

[15] Gershenson D.M.: "Management of early ovarian cancer: germ cell and sex cord-stromal tumors". Gynecol. Oneal., 1994, 55, S62.

[16] Gershenson D., Silva E., Levy L.: "Ovarian serous borderline tumors with invasive peritoneal implants". Cancer, 1998, 82, 1096.

[17] Lin P., Gershenson D., Bevers M.: "The current status of surgical staging of ovarian serous borderline tumors". Cancer, 1999, 85, 905.

[18] Baykal C., Al A., Demirol A., Bozdag G., Ayhan A.: "Twin pregnancy after ICSI in a patient with ovarian cancer complicated with maternal hepatitis C: case report". Eur. J. Obstet. Gynecol. Reprod. Biol., 2002, 102, 96.

[19] Morris R., Gershenson D., Silva E.: "Outcome and reproductive function after conservative surgery for borderline ovarian tumors". Obstet Gynecol., 2000, 95, 541.

[20] Mariani A., Webb M.J., Keeney G.L., Haddock M.G., Calori G., Podratz K.C.: "Low-risk corpus cancer: is lymphadenectomy or radiotherapy necessary?". Am. J. Obstet. Gynecol., 2000, 182, 1506.

[21] Watanabe M., Aoki Y., Kase H., Fujita K., Tanaka K.: "Low-risk endometrial cancer: a study of pelvic lymph node metastasis". Int. J. Gynecol Cancer, 2003, 13, 38.

[22] Takeshima N., Hirai Y., Tanaka N., Yamawaki T., Yamauchi K., Hasumi K.: "Pelvic lymph node metastasis in endometrial cancer with no myometrial invasion". Obst et. Gynecol., 1996, 88, 280.

[23] T he Society of Gynecologic Oncologists: "Guidelines for referral to a gynecologic oncologist: rationale and benefits". Gynecol. Oneal., 2000, 78, SI.

[24] Homesley H.D., Bundy B.N., Sedlis A., Yordan E., Berek J.S., Jahshan A., Mortel R.: "Assessment of current International Federation of Gynecology and Obstetrics staging of vulvar carcinoma relative to prognostic factors for survival (a Gynecologic Oncology Group study)". Am. J Obstet. Gynecol., 1991, 164, 997.

[25] Hacker N., Berek J., Lagasse L., Leuchter R., Moore J.: "Management of regional lymph nodes and their prognostic influence in vulvar cancer". Obstet. Gynecol., 1983, 61, 408.

[26] Eddy G., Copeland L., Gershenson D., Atkinson E., Wharton J., Rutledge F.: "Fallopian tube carcinoma". Obstet. Gynecol., 1984, 64, 546.

[27] Morgan M., Mikuta J.: "Surgical management of vulvar cancer". Surg. Oneal., 1999, 17, 168.

[28] DiSaia P., Creasman W.: "Invasive vulvar cancer". In: Clinical Gynecologic Oncology (eds.). St. Louis, Mosby Company, 2002, 211.